Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5702629 | Urologic Oncology: Seminars and Original Investigations | 2017 | 6 Pages |
Abstract
Although clinical staging and tumor size have been the key determinants in decision-making of patients with solid renal tumors, the histology-specific risks of metastatic potential are different for each mass. The definition of a SRM should be based on the metastatic potential and not on tumor size alone. This information could be helpful for counseling and managing patients with SRMs as well as for modifying active surveillance protocols.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Michael M.D., Dillon B.S., Oleg M.D., Srinivas M.D., Alexander M.D., Gennady M.D.,